This webinar explores how effective quality planning and preparation can enhance regulatory compliance for Pharma and Medtech companies. It covers the risks of receiving an FDA 483 or a Notified Body citation and highlights proactive steps like gap assessments and follow-up sessions to identify potential issues. Rather than relying solely on mock inspections, the session emphasizes strategic risk mitigation and expert preparedness to ensure compliance success.

Key Takeaways:

• Organizational readiness and SME training are crucial for demonstrating regulatory compliance in audits and inspections.
• Treat audits as “finals” rather than practice runs to ensure thorough preparation.
• Plan effective post-inspection corrective actions and communicate realistic timelines to regulatory bodies.